Related Experiment Video
Updated: May 5, 2026

Trace Fear Conditioning in Mice
Published on: March 20, 2014
Transient disturbances in contextual fear memory induced by Aβ(25-35) in rats are accompanied by cholinergic
Mikhail Stepanichev1, Natalia Lazareva1, Gulnur Tukhbatova2
1Laboratory of Functional Biochemistry of Nervous System, Russian Academy of Sciences, Moscow, Russia.
Abstract:
Damage to the medial septum (MS) or disruption of the septo-hippocampal pathway is often considered as a basis for memory impairments, manifesting in the hippocampus-dependent behavioral paradigms. In the present study, we have examined the effects of intracerebroventricular administration of aggregated amyloid-β (25-35) (Aβ(25-35)) on contextual fear conditioning and the condition of cholinergic neurons in the MS using immunohistochemical detection of choline acetyltransferase (ChAT) and expression of the "cholinergic locus genes" (ChAT and vesicular acetylcholine transporter (VaChT) mRNA). A single injection of Aβ(25-35) induced transient moderate impairments in contextual fear conditioning accompaniedby a decrease in ChAT expression. However, the long-term decline in ChAT and VaChT expression was not associated with stable impairments in contextual fear memory. An Aβ(25-35)-induced progressive decrease in the number of ChAT expressing neurons in the MS was revealed, but no gross neuronal cell loss in the MS could be detected (as judged by the density of NeuN-immunoreactive cells). Thus, Aβ(25-35) induced a loss of the cholinergic phenotype of septal neurons without neuronal cell death in MS. The data give an additional support to the concept of early impairments in the synthesis of proteins related to the cholinergic system as an important mechanism in amyloid-induced neuronal damage.
Related Concept Videos
Role of Amygdala in Memory
One of the...
Alzheimer Disease ll: Pathophysiology
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

